Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP301 in Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
NCT05698888Phase 1Terminated
- Sponsor
- Virtuoso Binco, Inc.
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of VP301 in multiple myeloma (MM), lymphoma and solid tumor (2 arms), sponsored by Virtuoso Binco, Inc. Primary endpoints: Occurrence of General Toxicity and Occurrence of Dose Limiting Toxicity at 21 days. Started Nov 2022; status: terminated.
02
Drugs
VP301
03
Conditions
multiple myeloma (MM)lymphomasolid tumor
Beyond the preview
Go deeper on NCT05698888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698888.